|
|
Exchange: |
Nasdaq National Market |
Security
Type: |
Common |
Shares
Out: |
21,110,000 |
Market
Cap: |
5.48(M) |
Last
Volume: |
4,769,812 |
Avg
Vol: |
4,756,792 |
52
Week Range: |
$0.2598 - $0.2598 |
|
Level
I Sector: |
Health Care |
Level
II Sector: |
Drugs |
Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
NASDAQ COMPOSITE |
|
NASDAQ NNM COMPOSITE |
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Plus Therapeutics is a clinical-stage pharmaceutical company focused on the development, manufacture and commercialization of treatments for patients battling cancer and other life-threatening diseases. The clinical stage drugs in Co.'s pipeline are: Rhenium NanoLiposomes, a radiotherapy for patients with recurrent glioblastoma; DocePLUS, a chemotherapy for patients with tumors that has been evaluated in a completed U.S. single-center Phase 1 clinical trial; and DoxoPLUS, a generic chemotherapy that has been evaluated in a completed, bioequivalence clinical trial in the U.S., Canada, and Ukraine versus Janssen's CAELYX® in patients with ovarian cancer.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
48,285 |
48,285 |
100,872 |
108,373 |
Total Buy Value |
$98,501 |
$98,501 |
$185,764 |
$199,106 |
Total People Bought |
6 |
6 |
6 |
6 |
Total Buy Transactions |
6 |
6 |
17 |
20 |
Total Shares Sold |
0 |
0 |
2,068 |
3,568 |
Total Sell Value |
$0 |
$0 |
$4,053 |
$4,525 |
Total People Sold |
0 |
0 |
1 |
2 |
Total Sell Transactions |
0 |
0 |
1 |
2 |
End Date |
2024-03-07 |
2023-12-05 |
2023-06-06 |
2022-06-06 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Holmes E Carmack |
Director |
|
2010-01-20 |
4 |
AS |
$9.00 |
$181,257 |
D/D |
(20,000) |
2,472 |
|
- |
|
Holmes E Carmack |
Director |
|
2010-01-20 |
4 |
OE |
$3.12 |
$65,900 |
D/D |
20,000 |
22,472 |
|
- |
|
Calhoun Christopher J |
Chief Executive Officer |
|
2009-12-21 |
4 |
D |
$5.71 |
$178,438 |
D/D |
(31,250) |
131,250 |
|
- |
|
Calhoun Christopher J |
Chief Executive Officer |
|
2009-12-21 |
4 |
OE |
$3.00 |
$187,500 |
D/D |
62,500 |
162,500 |
|
- |
|
Rickey David |
Director |
|
2009-12-18 |
4 |
OE |
$2.62 |
$20,111 |
I/I |
7,676 |
20,911 |
|
- |
|
Hawran Paul W |
Director |
|
2009-11-25 |
4 |
B |
$4.90 |
$24,500 |
D/D |
5,000 |
49,316 |
2.39 |
- |
|
Hawran Paul W |
Director |
|
2009-11-24 |
4 |
B |
$4.74 |
$23,700 |
D/D |
5,000 |
44,316 |
2.39 |
- |
|
Hawran Paul W |
Director |
|
2009-11-18 |
4 |
B |
$4.24 |
$84,900 |
D/D |
20,000 |
39,316 |
2.39 |
- |
|
Hawran Paul W |
Director |
|
2009-11-17 |
4 |
B |
$3.98 |
$19,900 |
D/D |
5,000 |
19,316 |
2.39 |
- |
|
Hawran Paul W |
Director |
|
2009-11-12 |
4 |
B |
$3.50 |
$35,000 |
D/D |
10,000 |
14,316 |
2.39 |
- |
|
Calhoun Christopher J |
Chief Executive Officer |
|
2009-05-20 |
4 |
B |
$2.92 |
$19,272 |
I/I |
6,600 |
36,850 |
2.58 |
- |
|
Calhoun Christopher J |
Chief Executive Officer |
|
2009-05-19 |
4 |
B |
$2.99 |
$9,718 |
I/I |
3,250 |
30,250 |
2.58 |
- |
|
Calhoun Christopher J |
Chief Executive Officer |
|
2009-05-18 |
4 |
B |
$2.83 |
$9,935 |
I/I |
3,500 |
27,000 |
2.58 |
- |
|
Calhoun Christopher J |
Chief Executive Officer |
|
2009-05-15 |
4 |
B |
$2.79 |
$9,765 |
I/I |
3,500 |
23,500 |
2.58 |
- |
|
Henriksen Ronald D |
Director |
|
2009-05-07 |
4 |
B |
$2.28 |
$50,160 |
D/D |
22,000 |
50,524 |
2.39 |
- |
|
Hedrick Marc H |
President |
|
2009-05-07 |
4 |
B |
$2.28 |
$45,600 |
D/D |
20,000 |
448,238 |
2.81 |
- |
|
Rickey David |
Director |
|
2009-05-07 |
4 |
B |
$2.28 |
$10,000 |
I/I |
4,386 |
13,235 |
2.1 |
- |
|
Rickey David |
Director |
|
2009-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
4,106 |
4,106 |
|
- |
|
Holmes E Carmack |
Director |
|
2009-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
2,472 |
2,472 |
|
- |
|
Hawkins Richard J |
Director |
|
2009-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
3,142 |
3,142 |
|
- |
|
Hawran Paul W |
Director |
|
2009-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
4,316 |
4,316 |
|
- |
|
Henriksen Ronald D |
Director |
|
2009-04-30 |
4 |
A |
$0.00 |
$0 |
D/D |
5,363 |
28,524 |
|
- |
|
Shirahama Norio Seijiro |
President - Asia Pacific |
|
2008-11-26 |
4 |
B |
$1.92 |
$4,800 |
D/D |
2,500 |
8,700 |
2.66 |
- |
|
Rickey David |
Director |
|
2008-11-21 |
4 |
B |
$1.90 |
$34,225 |
I/I |
17,500 |
34,909 |
2.1 |
- |
|
Rickey David |
Director |
|
2008-11-20 |
4 |
B |
$2.00 |
$27,720 |
I/I |
13,449 |
29,909 |
2.1 |
- |
|
340 Records found
|
|
Page 9 of 14 |
|
|